Does hepatic insulin resistance raise fasting glucose by failing to suppress hepatic glucose production?

The liver plays a central role in maintaining blood glucose homeostasis, particularly during the fasting state. In healthy physiology, insulin acts as a powerful brake on hepatic glucose production (HGP), ensuring that blood sugar remains within a narrow range while fasting.

Clinical evidence and glucose dynamics

• Fasting Hyperglycemia: In patients with type 2 diabetes (T2DM), fasting plasma glucose (FPG) levels are directly and strongly correlated with rates of hepatic glucose production. When hepatic insulin sensitivity is impaired, the liver continues to release glucose into the bloodstream even when insulin levels are elevated, leading to high FPG readings.
• Aging Factors: For an individual in their mid-70s, this process is often compounded by age-related metabolic changes. Increased hepatic steatosis (fatty liver) and mitochondrial dysfunction are common in older populations and are known to exacerbate hepatic insulin resistance, further driving inappropriate glucose output during the overnight fast.

Mechanistic explanations

• FoxO1 Pathway: At the molecular level, insulin normally triggers the phosphorylation of the transcription factor FoxO1, causing it to move from the nucleus to the cytoplasm. In the resistant state, FoxO1 remains in the nucleus, where it actively promotes the expression of rate-limiting gluconeogenic enzymes.
• Enzymatic Overexpression: This failure of FoxO1 sequestration leads to the over-transcription of Phosphoenolpyruvate carboxykinase (PEPCK) and Glucose-6-phosphatase (G6Pase). These enzymes drive the biochemical pathways of gluconeogenesis and glycogenolysis, essentially keeping the "glucose tap" turned on.
• Substrate Delivery: Hepatic resistance is often paired with increased delivery of gluconeogenic substrates (like glycerol and fatty acids) from adipose tissue, providing the liver with the raw materials needed to maintain high output.

Bottom line

The claim is well-supported: hepatic insulin resistance causes fasting hyperglycemia by preventing the insulin-mediated suppression of endogenous glucose production. This is driven by dysregulated FoxO1 signaling and remains a primary therapeutic target for managing blood sugar in aging populations.